Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme - Trial NCT01222221
Access comprehensive clinical trial information for NCT01222221 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Research UK and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
glioblastoma multiforme multipeptide vaccine IMA950
Interventional
biological
Sponsor & Location
Cancer Research UK
Timeline & Enrollment
Phase 1
Jul 01, 2010
Feb 01, 2015
Primary Outcome
Causality of each adverse event (AE) to glioblastoma multiform multi-antigen vaccine IMA950 and GM-CSF and AE severity according to NCI CTCAE Version 4.0,Total number of patients showing patient-individual T-cell responses against a single or multiple tumor-associated peptides (TUMAP) contained in the study vaccine IMA950 at one or more post-vaccination time points by HLA multimer analysis
Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response
 to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways
 to stop the growth of tumor cells, either by killing the cells or by stopping them from
 dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine
 therapy together with temozolomide and radiation therapy may kill more tumor cells.
 
 PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given
 together with temozolomide and radiation therapy in treating patients with newly diagnosed
 glioblastoma multiforme.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01222221
Non-Device Trial